Q-omics provides the consensus-scored CIZ1 profile across patient tissues and cancer cell-line models. CIZ1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CIZ1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CIZ1 protein abundance shows 23,283 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where CIZ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CIZ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CIZ1 survival associations across molecular data types. CIZ1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CIZ1 RNA expression–survival associations across cancer types. High CIZ1 expression shows unfavorable associations in ACC, LIHC, BLCA and LUSC, but favorable associations in UVM and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CIZ1 RNA expression.
This table summarizes CIZ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CIZ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CIZ1 shows higher tumor expression in HNSC, COAD, LIHC, KIRP, KIRC and CHOL. The HNSC box plot shows higher CIZ1 RNA expression in tumor versus normal tissue (log2 FC = +0.814, t-test p < 0.001).
This table shows molecular features associated with CIZ1 in patient tissues and cancer cell lines. In patient samples, CIZ1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CIZ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
